XBIO vs ARTV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 04, 2026

XBIO

57.7
AI Score
VS
XBIO Wins

ARTV

55.4
AI Score

Investment Advisor Scores

XBIO

58score
Recommendation
HOLD

ARTV

55score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric XBIO ARTV Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 12.0% -100.0% XBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 57.7/100 55.4/100 XBIO
Profit Margin -75.9% 0.0% ARTV
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

XBIO 1M: -47.3% · 3M: -21.4% ARTV 1M: -39.6% · 3M: -27.6%

Current Technical Phase

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 34.8 · Price: $2.24

ARTV

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 23

RSI (14): 22.6 · Price: $6.83

Fundamentals Snapshot

Metric XBIO ARTV
Market Cap — —
Forward P/E -6.6 -2.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% -1.0%
Gross Margin 1.0% —
Operating Margin -1.5% 0.0%
EPS -1.15 -3.23
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.